Clozapine for treatment-resistant bipolar disorder: a systematic review
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate the efficacy and safety of clozapine for treatment-resistant bipolar disorder (TRBD). METHODS: A systematic review of randomized controlled studies, open-label prospective studies, and retrospective studies of patients with TRBD was carried out. Interventions included clozapine monotherapy or clozapine combined with other medications. Outcome measures were efficacy and adverse drug reactions (ADRs). RESULTS: Fifteen clinical trials with a total sample of 1,044 patients met the inclusion criteria. Clozapine monotherapy or clozapine combined with other treatments for TRBD was associated with improvement in: (i) symptoms of mania, depression, rapid cycling, and psychotic symptoms, with many patients with TRBD achieving a remission or response; (ii) the number and duration of hospitalizations, the number of psychotropic co-medications, and the number of hospital visits for somatic reasons for intentional self-harm/overdose; (iii) suicidal ideation and aggressive behavior; and (iv) social functioning. In addition, patients with TRBD showed greater clinical improvement in long-term follow-up when compared with published schizophrenia data. Sedation (12%), constipation (5.0%), sialorrhea (5.2%), weight gain (4%), and body ache/pain (2%) were the commonly reported ADRs; however, these symptoms but did not usually require drug discontinuation. The percentage of severe ADRs reported, such as leukopenia (2%), agranulocytosis (0.3%), and seizure (0.5%), appeared to be lower than those reported in the published schizophrenia literature. CONCLUSION: The limited current evidence supports the concept that clozapine may be both an effective and a relatively safe medication for TRBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing Risk of Bias in Included Studies
Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch8 · Cited by 3,396 · cited 1×
“If the protocol was not available, outcomes listed in the methods section of the trial report were compared with the actually‐reported results (54).”
ResultLeucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · cited 1×
“Furthermore, meta‐analyses of randomized clinical trials (RCTs) (5, 6) and a recent review of effectiveness trials (7) supported the greater efficacy of clozapine among antipsychotics in schizophrenia.”
BackgroundMerikangas, K. R., Akiskal, H. S., Angst, J., Greenberg, P. E., Hirschfeld, R. M. A., Petukhova, M., & Kessler, R. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.5.543 · Cited by 2,399
Cross-national epidemiology of major depression and bipolar disorder
Weissman, M. M. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540040037030 · Cited by 2,302
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Phillips, M. R., Zhang, J., Shi, Q., Song, Z., Ding, Z., Pang, S., Li, X., Zhang, Y., & Wang, Z. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60660-7 · Cited by 1,063 · cited 1×
“Although mood disorder was traditionally considered a rather rare condition in China, recently conducted epidemiological studies in the country showed that it is one of the common mental disorders (32, 33), with a one-month prevalence of 6.”
BackgroundSelf-citationClozapine-induced agranulocytosis. incidence and risk factors in the united states
Alvir, J. M. J., Lieberman, J. A., Safferman, A. Z., Schwimmer, J. L., & Schaaf, J. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307153290303 · Cited by 967
Olanzapine versus placebo in the treatment of acute mania
Tohen, M., Sanger, T. M., McElroy, S. L., Tollefson, G. D., Chengappa, K. N. R., Daniel, D. G., Petty, F., Centorrino, F., Wang, R., Grundy, S. L., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.702 · Cited by 585
Effects of mood and subtype on cerebral glucose metabolism in treatment-resistant bipolar disorder
Ketter, T. A., Kimbrell, T. A., George, M. S., Dunn, R. T., Speer, A. M., Benson, B. E., Willis, M. W., Danielson, A., Frye, M. A., Herscovitch, P., et al. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00975-6 · Cited by 291
Suppes, T., Webb, A., Paul, B., Carmody, T., Kraemer, H., & Rush, A. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.8.1164 · Cited by 238
Cited by
Goodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
Solmi, M., Murru, A., Pacchiarotti, I., Undurraga, J., Veronese, N., Fornaro, M., Stubbs, B., Monaco, F., Vieta, E., Seeman, M., et al. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s117321 · Cited by 438
Aggression in autism spectrum disorder: presentation and treatment options
Fitzpatrick, S., Srivorakiat, L., Wink, L., Pedapati, E., & Erickson, C. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s84585 · Cited by 271
Bipolar depression: a major unsolved challenge
Baldessarini, R. J., Vázquez, G. H., & Tondo, L. (2020) · International Journal of Bipolar Disorders · doi:10.1186/s40345-019-0160-1 · Cited by 235
Musazzi, L., Treccani, G., & Popoli, M. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00060 · Cited by 83
Metadata
- Authors
- Li, X.-B., Tang, Y.-L., Wang, C.-Y., & de Leon, J.
- Venue
- Bipolar Disorders
- Publisher
- Wiley
- Published
- 2014-10-27
- Volume
- 17
- Issue
- 3
- Pages
- 235-247
- ISSN
- 1398-5647 (ISSN-L)
- OpenAlex
- W2134595880
- Cited by
- 146
- References
- 10
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.